Products for Research Use Only
RegisterLogin

LCKLSL

CAT: 0804-HY-P2333-01Size: 1 mgDry Ice: NoHazardous: No
Product image 1
1 / 1
CAT#:0804-HY-P2333-01Size:1 mg
Selected
24/48H Stock Items & 2 to 6 Weeks non Stock Items.
Quick Request Actions
Description
LCKLSL is a N-terminal hexapeptide and a competitive annexin A2 (AnxA2) inhibitor. LCKLSL potently inhibits the binding of tissue plasminogen activator (tPA) to AnxA2. LCKLSL also inhibits the generation of plasmin and has anti-angiogenic roles[1].
CAS Number
533902-29-3
UNSPSC
12352209
Target
Annexin A
Type
Peptides
Related Pathways
Cytoskeleton
Applications
Neuroscience-Neuromodulation
Field of Research
Cardiovascular Disease
Assay Protocol
https://www.medchemexpress.com/lcklsl.html
Purity
98.00
Solubility
H2O : ≥ 50 mg/mL
Smiles
CC(C)C[C@@H](C(O)=O)NC([C@H](CO)NC([C@H](CC(C)C)NC([C@H](CCCCN)NC([C@H](CS)NC([C@H](CC(C)C)N)=O)=O)=O)=O)=O
Molecular Formula
C30H57N7O8S
Molecular Weight
675.88
References & Citations
[1]Mallika Valapala, et al. A Competitive Hexapeptide Inhibitor of Annexin A2 Prevents Hypoxia-Induced Angiogenic Events. J Cell Sci. 2011 May 1;124 (Pt 9) :1453-64.
Shipping Conditions
Blue Ice
Storage Conditions
-80°C, 2 years; -20°C, 1 year (Powder, sealed storage, away from moisture)
Scientific Category
Peptides
Clinical Information
No Development Reported
Citation 01
Biomed Pharmacother. 2023 Mar:159:114173.|Inflamm Res. 2022 Sep;71 (9) :1067-1078.|iScience. 2025 Apr 2;28 (5) :112302.|J Immunother Cancer. 2025 Jun 26;13 (6) :e011716.|Biochem Pharmacol. 2025 Sep 6;242 (Pt 2) :117308.|Cell Commun Signal. 2024 Dec 21;22 (1) :616.|J Extracell Vesicles. 2024 Apr;13 (4) :e12425.|J Neurochem. 2022 Mar;160 (6) :662-674.

Alternative Products

CatalogName
GTR19029918LCKLSL
BUP01797-01LCKLSL hydrochloride
A24552-50LCKLSL 50mg
A24552-5LCKLSL 5mg
GTR19029739-01LCKLSL acetate
A24552-10LCKLSL 10mg
A24552-1LCKLSL 1mg
PP47394-01H-LCKLSL-OH

Popular Products